Luis A Diaz Jr
Overview
Explore the profile of Luis A Diaz Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
155
Citations
42952
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rousseau B, White J, Cercek A, Diaz Jr L
N Engl J Med
. 2025 Feb;
392(8):824-826.
PMID: 39970404
No abstract available.
2.
Foote M, White J, Chatila W, Argiles G, Lu S, Rousseau B, et al.
Clin Cancer Res
. 2024 Nov;
31(2):376-386.
PMID: 39561276
Purpose: Mutational data from multiple solid and liquid biospecimens of a single patient are often integrated to track cancer evolution. However, there is no accepted framework to resolve if individual...
3.
Ninni S, Vicario R, Coisne A, Woitrain E, Tazibet A, Stewart C, et al.
J Am Heart Assoc
. 2024 Aug;
13(17):e034255.
PMID: 39206728
Background: Cardiac surgery triggers sterile innate immune responses leading to postoperative complications. Clonal hematopoiesis (CH) is associated with short-term inflammation-mediated outcomes after cardiac surgery. The impact of CH on long-term...
4.
Rousseau B, Cercek A, Diaz Jr L
Nat Med
. 2024 Aug;
30(9):2407-2408.
PMID: 39117880
No abstract available.
5.
Ceyhan-Birsoy O, Fiala E, Rana S, Sheehan M, Kennedy J, Yelskaya Z, et al.
Haematologica
. 2024 Apr;
109(10):3383-3390.
PMID: 38572560
No abstract available.
6.
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients
Brahmer J, Long G, Hamid O, Garon E, Herbst R, Andre T, et al.
Eur J Cancer
. 2024 Jan;
199:113530.
PMID: 38295556
Background: Pembrolizumab has a manageable safety profile as described in its label, which was primarily based on 2799 patients who participated in clinical trials for melanoma or non-small cell lung...
7.
Harrold E, Foote M, Rousseau B, Walch H, Kemel Y, Richards A, et al.
Nat Med
. 2023 Oct;
29(10):2458-2463.
PMID: 37845474
Metastatic and localized mismatch repair-deficient (dMMR) tumors are exquisitely sensitive to immune checkpoint blockade (ICB). The ability of ICB to prevent dMMR malignant or pre-malignant neoplasia development in patients with...
8.
Le D, Diaz Jr L, Kim T, Van Cutsem E, Geva R, Jager D, et al.
Eur J Cancer
. 2023 May;
186:185-195.
PMID: 37141828
Background: Pembrolizumab demonstrated durable clinical benefit and manageable safety in previously treated advanced or metastatic microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer (CRC) in the phase 2 KEYNOTE-164 study....
9.
Paller C, Wang L, Fu W, Kumar R, Durham J, Azad N, et al.
Cancer Res Commun
. 2023 Mar;
3(2):338-346.
PMID: 36860652
Purpose: Mistletoe extract (ME) is widely used for patients with cancer to support therapy and to improve quality of life (QoL). However, its use is controversial due to suboptimal trials...
10.
Diplas B, Ptashkin R, Chou J, Sabwa S, Foote M, Rousseau B, et al.
JAMA Netw Open
. 2023 Feb;
6(2):e2254221.
PMID: 36729457
Importance: Clonal hematopoiesis (CH) has been associated with development of atherosclerosis and leukemia and worse survival among patients with cancer; however, the association with cancer therapy efficacy, in particular immune...